Wasserman and the colleagues demonstrated that Smad4 is closely associated with the high risk of recurrence or death of colorectal cancer patients, and the loss of Smad4 predicts worse clinical outcome, decreased immune infiltrate, and resistance to chemotherapy (Wasserman et al., 2018). This evidence concerns the gene SMAD4 and colorectal cancer.